Reference
·Primary source
DKSH Thailand healthcare segment revenue (2020-2024)
~CHF 1.2-1.4B (2024)
DKSH's Thailand healthcare segment recorded approximately CHF 1.2-1.4 billion in revenue in 2024 per group annual report segmentation, up from CHF 1.0 billion in 2020. Thailand is DKSH Group's single-largest country market for the healthcare business unit, contributing roughly 18-22% of segment revenue. The growth has been steady at 4-6% CAGR, materially underpinned by chronic-disease drug demand, originator-brand market expansion (oncology, biologics, diabetes), and the gradual ageing of Thailand's population. Operating margins in the segment hover around 5-7%, characteristic of high-volume regulated distribution.
Figure in context
DKSH's Thailand healthcare segment recorded approximately CHF 1.2-1.4 billion in revenue in 2024 per group annual report segmentation, up from CHF 1.0 billion in 2020. Thailand is DKSH Group's single-largest country market for the healthcare business unit, contributing roughly 18-22% of segment revenue. The growth has been steady at 4-6% CAGR, materially underpinned by chronic-disease drug demand, originator-brand market expansion (oncology, biologics, diabetes), and the gradual ageing of Thailand's population. Operating margins in the segment hover around 5-7%, characteristic of high-volume regulated distribution.
Interpretation notes
What this tells you
DKSH's Thailand healthcare segment recorded approximately CHF 1.2-1.4 billion in revenue in 2024 per group annual report segmentation, up from CHF 1.0 billion in 2020. Thailand is DKSH Group's single-largest country market for the healthcare business unit, contributing roughly 18-22% of segment revenue. The growth has been steady at 4-6% CAGR, materially underpinned by chronic-disease drug demand, originator-brand market expansion (oncology, biologics, diabetes), and the gradual ageing of Thailand's population. Operating margins in the segment hover around 5-7%, characteristic of high-volume regulated distribution.
What not to do with it
Values in CHF billion. Thailand healthcare segment revenue per DKSH country disclosure.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical distribution and wholesale revenue (2020-2024)
Pharmaceutical Research and Manufacturers Association, Ministry of Public Health Drug Information Center, Thai FDA
Thailand pharmaceutical distributor market share (2024)
DKSH Group investor disclosures, Zuellig Pharma corporate filings, PReMA member surveys
Thailand pharmacy chain store count (2020-2024)
Boots Thailand corporate disclosures, Watsons CK Hutchison investor materials, Pharmacy Council of Thailand registry
Thai FDA new drug registration approvals (2020-2024)
Thai Food and Drug Administration annual report, Ministry of Public Health, PReMA regulatory tracking
Government Pharmaceutical Organisation (GPO) state procurement
Government Pharmaceutical Organisation annual report, Ministry of Public Health, National Health Security Office
Thailand pharmaceutical cold-chain share of distribution
PReMA cold-chain working group, DKSH Thailand healthcare disclosure, Thai FDA Good Distribution Practice guidance
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.